title: Long-term Oncologic and financial implications of lung cancer screening.
abstract: Benefits and risks of computed tomography lung cancer screening are discussed with specific focus on oncologic and financial issues. Earlier disease stage at diagnosis implies that more patients are treated surgically, but the changes in oncologic treatment will not be dramatic. The crucial issue for implementation of screening will be that it is cost effective. Preliminary data from the National Lung Screening Trial indicate that it is cost effective and comparable to screening for other major malignancies. Some future modifications in the computed tomography screening methodology are discussed.
authors.affiliation: Department of Cardiothoracic Surgery, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen 2100, Denmark. Electronic address: jesper.holst.pedersen@rh.regionh.dk.
authors.forename: Jesper Holst
authors.initials: JH
authors.lastname: Pedersen
authors.affiliation: Department of Oncology, Finsen Centre, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen 2100, Denmark.
authors.forename: Jens Benn
authors.initials: JB
authors.lastname: Sørensen
mesh_terms: D003362:Cost-Benefit Analysis; D055088:Early Detection of Cancer / Q000191:economics* / Q000379:methods; D017048:Health Care Costs; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D008403:Mass Screening / Q000191:economics* / Q000379:methods; D011879:Radiotherapy Dosage; D012306:Risk; D014057:Tomography, X-Ray Computed / Q000191:economics* / Q000379:methods
keywords: Computed tomography screening future implementation; Cost effectiveness; Lung cancer screening; Oncologic implications